<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rod Passman, MD, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H86379230"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For patients with atrial fibrillation (AF), the two principal goals of long-term therapy are to improve quality of life (eg, symptom control) and to prevent associated morbidity and mortality (principally the prevention of thromboembolism). (See  <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm", section on 'Adverse hemodynamics in AF'</a> and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p>In asymptomatic patients with AF, there may be no need to pursue aggressive measures to maintain sinus rhythm, particularly in older individuals with longstanding persistent AF and without associated left ventricular dysfunction. For those patients who might feel better in sinus rhythm, rhythm-control strategies improve symptoms greater than rate control, but neither has been conclusively shown to improve survival compared with the other. The factors determining the choice between these two strategies are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>.)</p><p>For those patients in whom a rhythm control strategy is chosen, catheter ablation or antiarrhythmic drugs are the two principle therapeutic options. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a>.)</p><p>This topic will compare the efficacy and safety of these two options for rhythm control and provide recommendations for choosing one or the other.</p><p class="headingAnchor" id="H86379237"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The following terms are used in the classification of patients with atrial fibrillation (AF). In the studies discussed in this topic, some, but not all, of these groups have been included (see  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Classification and terminology'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paroxysmal (ie, self-terminating or intermittent)</strong> <strong>AF</strong> – Paroxysmal AF is defined as recurrent AF (≥2 episodes) that terminates spontaneously in seven days or less, usually less than 24 hours. (See  <a class="medical medical_review" href="/z/d/html/956.html" rel="external">"Paroxysmal atrial fibrillation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent AF</strong> – Persistent AF is defined as AF that fails to self-terminate within seven days. Episodes often require pharmacologic or electrical cardioversion to restore sinus rhythm. While a patient who has had persistent AF can have later episodes of paroxysmal AF, AF is generally considered a progressive disease. In individuals with paroxysmal AF, progression to persistent and permanent AF occurs in &gt;50 percent beyond 10 years despite antiarrhythmic therapy [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-standing persistent AF </strong>– Long-standing persistent AF refers to persistent AF that has lasted for one year or more [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Permanent AF</strong> – Permanent AF is a term used to identify individuals with persistent AF where a decision has been made to no longer pursue a rhythm control strategy. </p><p></p><p class="headingAnchor" id="H2981100924"><span class="h1">CATHETER ABLATION AND ANTIARRHYTHMIC DRUG THERAPY</span></p><p class="headingAnchor" id="H4285511895"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Catheter ablation uses either cryoablation (cryotherapy) or radiofrequency ablation (RFA). Pulse-field ablation, another promising energy source, is not yet approved by the United States Food and Drug Administration. AF recurrence, defined as an AF episode &gt;30 seconds in duration on cardiac monitoring, occurs in approximately 20 to 40 percent of patients at one year, although overall AF burden is often markedly decreased [<a href="#rid3">3</a>]. Important complications from catheter ablation include cardiac tamponade (1 percent), pulmonary vein stenosis (&lt;1 percent), phrenic nerve paralysis (up to 3 percent), and rare instances of stroke and atrioesophageal fistula [<a href="#rid4">4-6</a>]. These and other complications are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation", section on 'Complications'</a>.)</p><p> A 2017 randomized comparison between cryoablation and RFA showed similar success rates, as did a meta-analysis of observational studies [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/95704.html" rel="external">"Catheter ablation for the treatment of atrial fibrillation: Technical considerations for non-electrophysiologists"</a>.)</p><p>Commonly employed drugs to maintain sinus rhythm are <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">dronedarone</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, and <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>. Approximately 25 to 50 percent of people who receive antiarrhythmic medications will have recurrent AF within one year. Important side effects of antiarrhythmics include proarrhythmia, bradyarrhythmia, and organ toxicity in the case of amiodarone. (See  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a> and  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a>.)</p><p class="headingAnchor" id="H683565067"><span class="h2">Approach</span><span class="headingEndMark"> — </span>For patients with symptomatic paroxysmal AF in whom a rhythm rather than a rate control strategy is being pursued, either catheter ablation or AAD are reasonable first-line therapies. We suggest catheter ablation as first-line therapy over AAD in younger patients, patients who are poor candidates for AAD therapy, or in those concerned about the potential complications of AADs. Other factors that may impact the safety and efficacy of catheter ablation also need to be considered when deciding between catheter ablation and AAD. </p><p>For patients with symptomatic paroxysmal or persistent AF who have failed or become intolerant to one or more AADs, we recommend catheter ablation.</p><p>For patients with symptomatic persistent or longstanding persistent AF who have failed or become intolerant of one or more AADs or who choose not to start antiarrhythmic therapy, we suggest catheter ablation.</p><p class="headingAnchor" id="H86382142"><span class="h1">PATIENTS WITHOUT PRIOR ANTIARRHYTHMIC DRUG TREATMENT</span><span class="headingEndMark"> — </span>For patients who have chosen rhythm control and who have not previously received antiarrhythmic drug (AAD) therapy, either AAD or CA may be appropriate. All patients need to be informed of the possibility of recurrence of AF and AF-related symptoms and adverse events with both therapies. Recurrence rates and side effects are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"</a> and  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation", section on 'Complications'</a> and  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations", section on 'Drug-related arrhythmias and mortality'</a>.) </p><p>Until recently, catheter ablation (CA) was generally not offered as first-line therapy given the complexity of the procedure and the potential for complications. It was typically offered to patients who had failed AAD therapy. However, evidence suggests that CA is superior to AAD for control of symptoms. While CA appears superior to AAD for the prevention of AF recurrence, there is no evidence that the rates of cardiovascular death, myocardial infarction, or stroke differ between the two interventions. In addition, in the studies demonstrating superiority of CA, the procedure was performed by highly expert electrophysiologists. Thus, CA by an experienced operator may be considered as first-line therapy for symptomatic patients who, after a full discussion of the benefits and risks of both approaches, prefer an invasive approach.</p><p>This section will review the studies that have directly compared the two approaches as first-line therapy. These studies demonstrate that among the advantages of ablation, there is a greater reduction in AF recurrences, progression to persistent AF, and AF-related symptoms.</p><p>In a meta-analysis of six studies in 1200 patients comparing CA with AAD as first-line treatment for paroxysmal AF, CA was associated with [<a href="#rid9">9</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Lower rates of recurrent atrial arrhythmias (35 versus 53 percent; risk ratio [RR] 0.64, 95% CI 0.51-0.80) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar risks of serious adverse events (18 versus 21 percent; RR 0.87, 95% CI 0.58-1.30). Adverse events were defined differently across studies and included stroke, tamponade, and death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower rates of symptomatic atrial arrhythmias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower healthcare resource utilization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower rates of crossover to alternative treatment (RR 0.21, 95% CI 0.13-0.32). </p><p></p><p>Limitations of this study include a moderate degree of heterogeneity among the included studies; one study in particular accounted for most of the heterogeneity (the RAAFT 2 trial) [<a href="#rid10">10</a>].</p><p>A randomized study of 303 patients (EARLY-AF) compared initial rhythm-control therapy with catheter ablation with antiarrhythmic therapy in individuals with paroxysmal AF [<a href="#rid11">11</a>]. Over 36 months of follow-up the following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients assigned catheter ablation had less persistent AF compared with patients assigned to AADs (1.9 versus 7.4 percent; hazard ratio [HR] 0.25; 95% CI 0.09-0.70). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients assigned catheter ablation had less recurrent atrial tachyarrhythmia, which occurred in 87 patients in the ablation group (56.5 percent) and in 115 in the AAD group (77.2 percent; 56.5 versus 77.2 percent; HR 0.51; 95% CI 0.38-0.67). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serious adverse events occurred in seven patients (4.5 percent) in the ablation group and in 15 (10.1 percent) in the AAD group.</p><p></p><p>Limitations of this study include the sole use of cryoballoon ablation and the exclusion of patients with persistent AF. </p><p class="headingAnchor" id="H173203350"><span class="h1">PATIENTS WITH PRIOR ANTIARRHYTHMIC DRUG TREATMENT</span><span class="headingEndMark"> — </span>For patients with either paroxysmal or persistent (see <a class="local">'Classification'</a> above) AF who seek to reduce their symptom burden and have received treatment with at least one effective antiarrhythmic drug, the option of continuing AAD or undergoing AF ablation should be based on the success and tolerability of AAD therapy along with patient preference. The patient's choice will be guided by advantages and burdens of each approach. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a>.) </p><p>This section will review the studies that have directly compared the two approaches. These studies suggest that although catheter ablation and antiarrhythmic drug therapy lead to similar rates of all-cause mortality and other serious morbidities, there may be a greater improvement in quality of life with the former. </p><p>This topic is not intended to address management in patients who have failed rhythm control with two or more antiarrhythmic drugs or those who have already received catheter ablation. Failure of an antiarrhythmic drug is defined as a drug trial that results in a reduction in AF burden that is not satisfactory to the patient, or results in side effects that are intolerable to the patient, proarrhythmia, or organ toxicity. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations", section on 'Long-term issues'</a>.)</p><p>Three early meta-analyses of studies comparing catheter ablation and antiarrhythmic drug therapy found that recurrence of AF occurred less often in patients who received catheter ablation in the 12 months after initiation of therapy [<a href="#rid12">12-14</a>]. The following three randomized trials directly compared catheter ablation with antiarrhythmic drug therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>The ThermoCool AF study randomly assigned 167 symptomatic patients with paroxysmal AF (no episodes lasting more than 30 days) who did not respond to at least one AAD and who experienced at least three episodes of paroxysmal AF within six months before randomization to either catheter ablation (with RFA) or AAD therapy in a 2:1 fashion [<a href="#rid15">15</a>]. Patients with significant left ventricular dysfunction, persistent AF, and advanced heart failure were excluded. Catheter ablation included pulmonary vein isolation with confirmation of entrance block, and AAD therapy included <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> (36 percent), <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a> (41 percent), <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, or <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> at the investigator's discretion. After nine months, there were significantly fewer patients with documented symptomatic paroxysmal AF in the catheter ablation group (16 versus 66 percent; hazard ratio 0.30, 95% CI 0.19-0.47). In addition, major treatment-related adverse events occurred more often with AAD therapy (9 versus 5 percent) at 30 days. Mean quality-of-life scores improved significantly with catheter ablation compared to AAD therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The STOP AF trial randomly assigned 245 paroxysmal AF patients (in a 2:1 manner) to cryoballoon ablation or drug therapy [<a href="#rid16">16</a>]. Patients had previously failed drug therapy; paroxysmal and early persistent AF were present in 78 and 22 percent, respectively. Treatment success was defined as freedom from chronic treatment failure, as defined by the absence of: any detectable AF after the blanking period; use of a non-study antiarrhythmic drug; and any non-protocol intervention for AF. At 12 months, the primary end point was present in 69.9 and 7.3 percent of the two groups (p&lt;0.001). Serious adverse procedure-related events occurred in 3.1 percent. Phrenic nerve palsy occurred in 11.2 percent, but resolved in the majority.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) trial randomly assigned 2204 patients with paroxysmal (43 percent) or persistent AF (57 percent) to catheter ablation or antiarrhythmic drug therapy [<a href="#rid17">17</a>]. Patients were excluded if they had a prior catheter ablation or had failed two or more antiarrhythmic drugs. The following findings were noted:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the patients who received antiarrhythmic drug therapy, 27.5 percent crossed over to the ablation group. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The primary composite end point (death, disabling stroke, serous bleeding, or cardiac arrest) occurred in 8.0 and 9.2 percent of the two groups, respectively (hazard ratio [HR] 0.86, 95% CI 0.65-1.15), during a median follow-up of about four years. There was no difference in all-cause mortality (5.2 versus 6.1 percent; HR 0.85, 95% CI 0.60-1.21). The end point of death or cardiovascular hospitalization occurred less often with catheter ablation (51.7 versus 58.1 percent; HR 0.83, 95% CI 0.74-0.93), as did the rate for AF recurrence (49.9 versus 69.5 percent; HR 0.52, 95% CI 0.45-0.60).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both patient groups achieved significant improvement in quality-of-life scores, and the improvement in the catheter ablation group was significantly greater than in the drug therapy group. Using one quality-of-life tool, the mean score at baseline was approximately 63 points. At 12 months, the scores were 80.9 and 86.4 points, respectively [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Catheter Ablation compared with optimized Pharmacological Therapy for Atrial Fibrillation (CAPTAF) trial randomly assigned 155 patients with symptomatic persistent or paroxysmal AF to catheter ablation or antiarrhythmic drug therapy [<a href="#rid19">19</a>]. The primary end point, SF-36 General Health score, improved more in the ablation group than the drug therapy group from baseline to 12 months (mean baseline score, 61.8 versus 62.7; mean change 11.9 versus 3.1, respectively; p = 0.003).</p><p></p><p class="headingAnchor" id="H20828503"><span class="h2">Patients with heart failure</span><span class="headingEndMark"> — </span>Mortality and morbidity are higher among patients with atrial fibrillation and heart failure than among those with heart failure alone. Adverse events due to antiarrhythmic drug therapy appear to be higher in patients with heart failure and reduced ejection fraction. Catheter ablation for atrial fibrillation has been proposed as a means of improving outcomes among patients with heart failure who are otherwise receiving appropriate treatment. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure", section on 'Catheter ablation'</a>.)</p><p class="headingAnchor" id="H86379335"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Recommendations for the use of catheter ablation are available in societal guidelines. The 2016 European Society of Cardiology guideline recommends catheter ablation for patients with symptomatic, paroxysmal, persistent, and probably long-standing persistent atrial fibrillation who have failed (or are intolerant to) treatment with at least one antiarrhythmic drug [<a href="#rid20">20</a>]. </p><p>The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation makes the following recommendations regarding catheter ablation (CA) to maintain sinus rhythm [<a href="#rid21">21</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>CA is useful for symptomatic paroxysmal AF refractory or intolerant to at least one class I or III antiarrhythmic medication when a rhythm control strategy is desired.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CA is reasonable for selected patients with symptomatic persistent AF refractory or intolerant to at least one class I or III antiarrhythmic medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CA may be considered for symptomatic long-standing (&gt;12 months) persistent AF refractory or intolerant to at least one class I or III antiarrhythmic medication, when a rhythm control strategy is desired.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CA may be considered prior to initiation of antiarrhythmic drug therapy with a class I or III antiarrhythmic medication for symptomatic paroxysmal AF when a rhythm control strategy is desired.</p><p></p><p class="headingAnchor" id="H3376477994"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H86379342"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without prior antiarrhythmic drug treatment </strong>– For most patients with new-onset <strong>symptomatic paroxysmal</strong> atrial fibrillation (AF) who have chosen a rhythm rather than a rate control strategy, both antiarrhythmic drug (AAD) therapy or catheter ablation (CA) can be considered as initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients who may reasonably prefer CA as initial therapy include those who are concerned about the potential complications of AAD or the higher rate of AF recurrence with it. (See <a class="local">'Patients without prior antiarrhythmic drug treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with prior antiarrhythmic drug treatment </strong>–<strong> </strong>For patients with <strong>symptomatic paroxysmal or persistent</strong> AF and who have failed or become intolerant to one or more AAD, we recommend CA (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Patients with prior antiarrhythmic drug treatment'</a> above.) </p><p></p><p class="bulletIndent1">For patients with <strong>symptomatic persistent or longstanding persistent</strong> AF who have failed or become intolerant of one<strong> </strong>or more AAD or who choose not to start antiarrhythmic therapy, we suggest CA (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Patients with prior antiarrhythmic drug treatment'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wilber DJ. Pursuing sinus rhythm in patients with persistent atrial fibrillation: when is it too late? J Am Coll Cardiol 2009; 54:796.</a></li><li><a class="nounderline abstract_t">European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.</a></li><li><a class="nounderline abstract_t">Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation 2019; 140:1779.</a></li><li><a class="nounderline abstract_t">Teunissen C, Velthuis BK, Hassink RJ, et al. Incidence of Pulmonary Vein Stenosis After Radiofrequency Catheter Ablation of Atrial Fibrillation. JACC Clin Electrophysiol 2017; 3:589.</a></li><li><a class="nounderline abstract_t">Samuel M, Almohammadi M, Tsadok MA, et al. Population-Based Evaluation of Major Adverse Events After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol 2017; 3:1425.</a></li><li><a class="nounderline abstract_t">Tilz RR, Schmidt V, Pürerfellner H, et al. A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J 2023; 44:2458.</a></li><li><a class="nounderline abstract_t">Kuck KH, Fürnkranz A, Chun KR, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J 2016; 37:2858.</a></li><li><a class="nounderline abstract_t">Buiatti A, von Olshausen G, Barthel P, et al. Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies. Europace 2017; 19:378.</a></li><li><a class="nounderline abstract_t">Imberti JF, Ding WY, Kotalczyk A, et al. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart 2021; 107:1630.</a></li><li><a class="nounderline abstract_t">Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014; 311:692.</a></li><li><a class="nounderline abstract_t">Andrade JG, Deyell MW, Macle L, et al. Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. N Engl J Med 2023; 388:105.</a></li><li><a class="nounderline abstract_t">Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008; 168:581.</a></li><li><a class="nounderline abstract_t">Terasawa T, Balk EM, Chung M, et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med 2009; 151:191.</a></li><li><a class="nounderline abstract_t">Chen HS, Wen JM, Wu SN, Liu JP. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev 2012; :CD007101.</a></li><li><a class="nounderline abstract_t">Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303:333.</a></li><li><a class="nounderline abstract_t">Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013; 61:1713.</a></li><li><a class="nounderline abstract_t">Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA 2019; 321:1261.</a></li><li><a class="nounderline abstract_t">Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA 2019; 321:1275.</a></li><li><a class="nounderline abstract_t">Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA 2019; 321:1059.</a></li><li><a class="nounderline abstract_t">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.</a></li><li><a class="nounderline abstract_t">Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14:e275.</a></li></ol></div><div id="topicVersionRevision">Topic 93920 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19695456" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pursuing sinus rhythm in patients with persistent atrial fibrillation: when is it too late?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20802247" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31630538" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759432" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of Pulmonary Vein Stenosis After Radiofrequency Catheter Ablation of Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759674" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Population-Based Evaluation of Major Adverse Events After Catheter Ablation for Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37062040" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27381589" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27702864" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34261737" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549549" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36342178" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Progression of Atrial Fibrillation after Cryoablation or Drug Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18362249" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581635" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513945" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Catheter ablation for paroxysmal and persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20103757" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23500312" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874766" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874716" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874754" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506916" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
